Life sciences company Thermo Fisher (NYSE:TMO) will be announcing earnings results this Wednesday before the bell. Here’s what investors should know.
Thermo Fisher beat analysts’ revenue expectations by 1.3% last quarter, reporting revenues of $10.36 billion, flat year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ organic revenue estimates but a slight miss of analysts’ operating income estimates.
Is Thermo Fisher a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Thermo Fisher’s revenue to grow 1.4% year on year to $10.69 billion, a reversal from the 1.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.24 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Thermo Fisher has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Thermo Fisher’s peers in the life sciences tools & services segment, only Medpace has reported results so far. It beat analysts’ revenue estimates by 11.3%, delivering year-on-year sales growth of 14.2%.
Read our full analysis of Medpace’s earnings results here.Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.1% on average over the last month. Thermo Fisher is up 3.7% during the same time and is heading into earnings with an average analyst price target of $546.08 (compared to the current share price of $414.99).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.